연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
3191. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Schmid P, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia JA, Zhou X, Haiderali A, Nguyen AM, Cortes J, Winer EP.
Eur J Cancer 2023 Dec:195:113393
Link
3190. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Takahashi M, Cortés J, Dent R, Pusztai L, McArthur H, Kümmel S, Denkert C, Park YH, Im SA, Ahn JH, Mukai H, Huang CS, Chen SC, Kim MH, Jia L, Li XT, Tryfonidis K, Karantza V, Iwata H, Schmid P
JAMA Netw Open
2023 Nov 1;6(11):e2342107.
Link
3189. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, de Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S
Clin Cancer Res 2024 Jan 5;30(1):50-62.
Link
3188. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V.
Future Oncol 2023 Nov 2. [Epub ahead of print]
Link
3187. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
Soo Yeon Baek, Woo Chul Noh, Sei-Hyun Ahn, Hyun-Ah Kim, Jai Min Ryu, Seung Il Kim, Eun-Gyeong Lee, Seock-Ah Im, Yongsik Jung, Min Ho Park, Kyong Hwa Park, Su Hwan Kang, Joon Jeong, Eunhwa Park, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Woosung Lim
; Seonok Kim, MSc18 ; and Hee Jeong Kim, MD, PhD
J Clin Oncol 2023 Nov 1;41(31):4864-4871.
Link
3186. Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers
Nikas IP, Lim S, Im S-A, Lee K-H, Lee D-W, Lee H, Ryu HS
Pathobiology 2023 Oct 10. [Epub ahead of print]
Link
3185. Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda, Seung-Wan Ryu, Takashi Ishikawa, Hye Jin Kang, Kazuhito Nabeshima, Seock-Ah Im, Toshio Shimokawa, Yoon-Koo Kang, Seiichi Hirota, Han-Kwang Yang & Toshirou Nishida
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2023 Sep;26(5):775-787.
Link
3184. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Sara M Tolaney, Arlene Chan, Katarina Petrakova , Suzette Delaloge , Mario Campone , Hiroji Iwata, Parvin F Peddi , Peter A Kaufman , Elisabeth De Kermadec , Qianying Liu , Patrick Cohen , Gautier Paux , Lei Wang , Nils Ternès , Eric Boitier , Seock-Ah Im
J Clin Oncol 2023 Aug 20;41(24):4014-4024
Link
3183. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz , Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios , Aditya Bardia , Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi
Ther Adv Med Oncol 2023 May 29;15:17588359231178125.
Link
3182. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Perna, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock-Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laurentiis , Noelia Martínez Jañez , Barbara Adamo , Keun Seok Lee , Kyung Hae Jung , Gábor Rubovszky , Ling-Ming Tseng , Yen-Shen Lu , Yuan Yuan , Micah J Maxwell, Vincent Haddad , Sabrina S Khan , Hope S Rugo , Barbara Pistilli
Future Oncol 2023 Jun 30 [Epub ahead of print]
Link